Astrazeneca

FromAstraZeneca ([email protected])
Subject (50)Baxdrostat met primary endpt in BaxHTN PhIII trial
Preheader (146)Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
Typography
Arial
Colors
Text Analysis
Body Words135
Subject Words8
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px716 px
X-Spam Score-0.1
Preheader OptimizedNo
Timing
Day of WeekThursday
TimeEarly Morning

Baxdrostat met primary endpt in BaxHTN PhIII trial

Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension
Baxdrostat met primary endpt in BaxHTN PhIII trial